Cleveland Cord Blood Center

Name

Cleveland Cord Blood Center

Legal name

Cleveland Cord Blood Center

Website

https://clevelandcordblood.org

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Cord Blood Banking & Cellular Therapy Services

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Blood, Organ & Tissue Donation Organizations (BPAGACAJ), Plasma-Derived & Blood Products Distributors (HLAIAJAJ)

Keywords

• Cord blood banking
• Stem cell storage
• Cellular therapy manufacturing
• Hematopoietic transplantation
• Public cord blood bank

Headquarters

HQ city

Cleveland

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Cord Blood Unit Distribution: Distribution of cord blood stem cell units to transplant centers worldwide through international registries. Units are searched and accessed through NMDP/Be The Match and Bone Marrow Donors Worldwide registries.
2. Research Materials Supply: Supply of cord blood units to researchers and research organizations for regenerative medicine and immunotherapy applications.
3. Cell Therapy Manufacturing Services: Cleveland Cell Therapy Incubator (CCTI) provides manufacturing services for clinical-grade cell products using cord blood-derived materials for pharmaceutical partners including Deverra Therapeutics and Glycostem Therapeutics.
4. CLEVECORD Product Sales: Sales of FDA-licensed CLEVECORD stem cell product for unrelated hematopoietic cell transplantation.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

The Cleveland Cord Blood Center is a not-for-profit public cord blood bank that collects, processes, stores, and distributes stem-cell rich umbilical cord blood units for transplantation in patients with life-threatening disorders such as leukemia, lymphoma, and immune system disorders. Its FDA-licensed CLEVECORD product enables unrelated hematopoietic cell transplantation, while its CCTI subsidiary provides GMP-compliant cell therapy manufacturing services to biotech and pharmaceutical partners. The organization also conducts research programs in wound healing, Parkinson's disease, diabetic retinopathy, and iTreg cell therapy development.

Product overview

The Cleveland Cord Blood Center operates as a not-for-profit public cord blood bank offering a comprehensive suite of cord blood banking and cellular therapy services. The core offering is the FDA-licensed CLEVECORD™ stem cell product for hematopoietic transplantation. The organization operates two subsidiaries: Cleveland Cell Therapy Incubator (CCTI) for GMP-compliant cell therapy manufacturing and development services, and Advanced Immune Cellular Therapeutics (AICT) for preclinical T reg cell research. The portfolio includes internal research programs in wound healing, Parkinson's disease, diabetic retinopathy, and iTreg cell therapy, supported by a network of hospital collection sites across Ohio, Georgia, and California.

Differentiator

Problem solved

Functional benefit

Brands

• CLEVECORD: FDA-licensed stem cell product (HPC, Cord Blood) derived from umbilical cord blood for use in unrelated hematopoietic cell transplantation in patients with disorders affecting the hematopoietic system such as leukemia, lymphoma and immune system disorders

Products and services

• CLEVECORD FDA-licensed stem cell product (HPC, Cord Blood) derived from umbilical cord blood, authorized for use in unrelated hematopoietic cell transplantation in patients with disorders affecting the hematopoietic system such as leukemia, lymphoma, and immune system disorders.
• Cord Blood Banking Services Collection, processing, testing, frozen storage, and distribution of stem-cell rich umbilical cord blood for transplantation in patients with life-threatening disorders. Services include hospital-based collection at partner sites, processing and cryopreservation at the Warrensville Heights facility, listing on international registries (NMDP/Be The Match, Bone Marrow Donors Worldwide), and worldwide distribution to transplant centers.
• Cleveland Cell Therapy Incubator (CCTI) Manufacturing Services GMP-compliant contract manufacturing services for clinical-grade cell products using cord blood-derived materials. CCTI serves as the production hub for biotech and pharmaceutical partners developing allogeneic off-the-shelf cord blood-derived cell therapies, including supply of clinical-grade liquid cord blood units and expanded cord blood progenitors and immune cells for FDA-approved clinical studies. Partners include Deverra Therapeutics and Glycostem Therapeutics.
• Advanced Immune Cellular Therapeutics (AICT) Research Services Preclinical research program focused on enhancing T regulatory cells (T reg) to develop advanced cellular therapies for diseases of the immune system. Operates an animal laboratory for translational research advancing CCBC's pipeline of cord blood-derived cellular therapeutics.
• Hospital Cord Blood Collection Site Network
• Research Materials Supply

Quantifiable outcome

• 77% bone marrow match likelihood for Caucasian patients vs 23-41% for African American/Asian patients
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Deverra TherapeuticscoreStrategic or Co-development Partner · 5 April 2022Deverra Therapeutics, a clinical-stage company developing therapeutic allogeneic off-the-shelf cord blood-derived cell products, entered into a manufacturing service agreement with CCBC's Cleveland Cell Therapy Incubator (CCTI). CCTI serves as the production hub for clinical-grade expanded cord blood progenitors and immune cells using Deverra's proprietary manufacturing platforms to support FDA-approved clinical studies. The collaboration began in 2018 with supply programs and extended to manufacturing for Deverra's mid-stage clinical development programs.
• Kaiser Permanente San Leandro Medical CentercoreChannel Partner/ Reseller/ Distributor · 13 July 2021Kaiser Permanente San Leandro Medical Center became the first hospital in the East Bay to offer cord blood donation through partnership with CCBC. The hospital is located in one of the most diverse communities, helping expand CCBC's diverse cord blood inventory. Supported by the California Umbilical Cord Blood Collection Program.
• Glycostem TherapeuticscoreStrategic or Co-development Partner · 1 July 2021Glycostem Therapeutics B.V., a clinical-stage company focused on therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, entered into an agreement with CCBC's Cleveland Cell Therapy Incubator (CCTI). CCTI supplies Glycostem with clinical-grade liquid cord blood units for development of cellular immunotherapy cancer treatments. This supply chain includes additional testing and intensive reviews for clinical-grade manufacturing. Glycostem is a European entity entering the U.S. market.
• Kaiser Permanente San Francisco Medical CentercoreChannel Partner/ Reseller/ Distributor · 26 July 2017Kaiser Permanente San Francisco Medical Center became the first hospital in San Francisco to offer expectant parents the opportunity to donate their babies' umbilical cord blood to a public cord blood bank. Supported by the California Umbilical Cord Blood Collection Program. A CCBC-trained team collects and prepares cord blood for shipment to the Northeast Ohio center.
• Piedmont Atlanta HospitalcoreChannel Partner/ Reseller/ DistributorPartner hospital collection site where cord blood is collected for CCBC. Atlanta was CCBC's first out-of-state collection site. 70% of cord blood units from Emory Hospital are considered diverse units. Collection sites help increase diversity of CCBC's cord blood units.
• Emory University Hospital MidtowncoreChannel Partner/ Reseller/ DistributorPartner hospital collection site in Atlanta where cord blood is collected for CCBC. 70% of cord blood units from Emory Hospital are considered diverse units, contributing significantly to CCBC's diversity goals.
• Cleveland Clinic Hillcrest HospitalcoreChannel Partner/ Reseller/ DistributorPartner hospital collection site with the busiest OB hospital in the area and diverse population. The hospital was tremendously supportive in establishing the cord blood collection program.
• Cleveland Clinic Fairview HospitalcoreChannel Partner/ Reseller/ DistributorPartner hospital collection site in Cleveland where expectant parents can donate their baby's cord blood. Not every hospital provides this opportunity, making Fairview Hospital stand out.
• Alta Bates Summit Medical CenterminorChannel Partner/ Reseller/ DistributorPartner hospital collection site in Berkeley, California.
• California Umbilical Cord Blood Collection ProgramcoreStrategic or Co-development PartnerStatewide public program supporting collection of cord blood units from diverse populations for public banking. Supports CCBC's West Coast collection sites (Kaiser Permanente San Francisco and San Leandro).
• National Marrow Donor Program (NMDP)/Be The MatchcoreStrategic or Co-development PartnerInternational registry through which CCBC's cord blood stem cell units are searched and accessed by transplant doctors. CCBC participates in NMDP's National Cord Blood Inventory program.
• Cord Blood AssociationminorStrategic or Co-development PartnerInternational non-profit organization promoting public and family cord blood banking. CCBC Executive Director Marcie Finney serves on the CBA Board of Directors.
• Health Resources & Services Administration (HRSA)coreStrategic or Co-development PartnerFederal agency. CCBC has contracted with HRSA's National Cord Blood Inventory to support contribution to a national inventory of stem cells.
• Case Western Reserve UniversityminorStrategic or Co-development PartnerCollaboration on wound healing research and Parkinson disease research. Jonathan Kenyon was a Postdoctoral Scholar and Fellow at Case Western before joining CCBC. Partnership includes Case Western Reserve University Institutional Animal Care and Use Committee for animal testing.

Scale indicators7 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• StemCyte: A public-private hybrid cord blood bank operating internationally with FDA-licensed cord blood products and therapeutic development programs. Directly comparable to CCBC as another FDA-licensed cord blood center offering both transplantation products and cell therapy research applications.
• Carolinas Cord Blood Bank: One of the largest public cord blood banks in the U.S., also FDA-licensed, that collects, processes, and distributes cord blood units for transplantation through NMDP/Be The Match. Directly comparable operating model and customer base to CCBC.
• National Cord Blood Program (New York Blood Center): Operates the National Cord Blood Program, one of the largest and oldest public cord blood banks in the U.S. Both are public cord blood banks that collect, process, store, and distribute cord blood units through international registries for transplantation—directly comparable core operations.

Emerging players

• Deverra Therapeutics: A clinical-stage biotech developing allogeneic off-the-shelf cord blood-derived cell products, with CCBC's CCTI serving as its manufacturing partner for FDA-approved clinical studies. Comparable in the cord blood-derived cell therapy space, representing both a partner and emerging therapeutic competitor.
• Glycostem Therapeutics: A clinical-stage Dutch biotech developing allogeneic Natural Killer cell therapies from cord blood, which sources clinical-grade liquid cord blood units from CCBC's CCTI. Operates in the same cord blood-derived cellular immunotherapy space as CCBC's research programs.

Broad incumbents

• ViaCord (Revvity): A leading family cord blood banking service owned by Revvity (formerly PerkinElmer). Comparable cord blood banking service for expectant parents, though private/family-focused rather than public donation like CCBC.
• Cord Blood Registry (CBR) by California Cryobank: One of the largest family cord blood banks in the U.S., now part of California Cryobank. Operates in the same cord blood banking industry as CCBC but serves the private/family banking segment with different business model.
• Cryo-Cell International: The first private family cord blood bank in the world, offering cord blood and cord tissue storage services to families. Comparable as a major cord blood banking operator serving U.S. consumers, though focused on private/family banking rather than public donation.

Regional players

• LifeSouth Community Blood Centers: A community blood center operating cord blood banking programs in the Southeastern U.S. Comparable as a public cord blood bank with hospital-based collection sites, though primarily regional in focus.

Others

• NMDP/Be The Match: The National Marrow Donor Program operates the registry through which CCBC's cord blood units are distributed to transplant centers worldwide. Functions as a critical ecosystem enabler and distribution channel for CCBC rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/clevecordblood
• Facebookfacebook.com/clevecordblood
• LinkedInlinkedin.com/company/cleveland-cord-blood-center

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cleveland Cord Blood Center